Abstract
Aim
This study was a retrospective analysis of our experience with severe cross-hypersensitivity reactions (HSR) to the taxanes paclitaxel (P) and docetaxel (D) in patients with breast cancer.
Patients and methods
We evaluated patients with breast cancer treated with P or D who experienced severe HSR to one of the two taxanes. Severe HSR was defined as any reaction severe enough to warrant discontinuation of the drug. Initial intravenous premedication for paclitaxel was dexamethasone (20 mg), ranitidine (50 mg) and dexchlorpheniramine (10 mg). For docetaxel, dexamethasone (4 mg) orally every 12 hours was administered the day before infusion and dexamethasone (20 mg) was administered intravenously prior to infusion. After severe HSR to the taxane and 30 minutes before infusion of another taxane, we administered dexamethasone (20 mg), ranitidine (50 mg) and dexchlorpheniramine (10 mg) iv as a premedication, and we also increased the time of the infusion.
Results
Between March 2009 and April 2010, 23 patients experienced an initial severe HSR to taxane (12 P, 11 D). Substitution of another taxane was conducted in 17 patients in the two weeks following the initial HSR. Eight patients had an initial HSR with P, and three had a cross-HSR to D. Nine patients had an initial HSR to D, and four of these patients had a cross-HSR to P. Among the 17 patients who received both taxanes, 7 (41%) had a cross-HSR. All cross-HSRs were sufficiently severe (grade 3–4) to suspend taxane treatment permanently. In the remaining 6 patients, a desensitisation protocol to taxanes was performed by increasing the dose of the diluted drug (4 P, 2 D), which resulted in administration of the drug without complications in all cases. There were no treatment-related deaths.
Conclusion
Severe cross-HSR between P and D occurred in a significant proportion of our patients with breast cancer, so care must be taken when substituting taxanes (paclitaxel and docetaxel). A desensitisation protocol can be an effective alternative to decrease the risk of a new HSR.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Crown J, O’Leary M, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9[Suppl 2]:24–32
Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268
Dizon DS, Schwartz J, Rojan A et al (2006) Cross-sensitivity between paclitaxel and docetaxel in a women’s cancers program. Gynecol Oncol 100:149–151
Moon C, Verschraegen CF, Bevers M et al (2000) Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 11:565–568
Lokich J, Anderson N (1998) Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 9:573
Denman JP, Gilbar PJ, Abdi EA (2002) Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. J Clin Oncol 20:2760–2761
Essayan DM, Kagey-Sobotka A, Colarusso PJ et al (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42–46
Feldweg AM, Lee CW, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96:824–829
Fishman A, Gold T, Goldberg A et al (1999) Effective desensitization protocol to paclitaxel following hypersensitivity reaction. Int J Gynecol Cancer 9:156–159
Castells MC, Tennant NM, Sloane DE et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574–580
Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803
Gradishar WJ, Krasnojon D, Cheporov S et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611–3619
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sánchez-Muñoz, A., Jiménez, B., García-Tapiador, A. et al. Cross-sensitivity between taxanes in patients with breast cancer. Clin Transl Oncol 13, 904–906 (2011). https://doi.org/10.1007/s12094-011-0753-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0753-3